Supernus Pharmaceuticals
SUPN
249 hedge funds and large institutions have $1.72B invested in Supernus Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 91 increasing their positions, 89 reducing their positions, and 38 closing their positions.
640% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $343K
2.7% more ownership
Funds ownership: 102.44% → 105.13% (+2.7%)
2% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 89
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 258 → 249 (-9)
14% less capital invested
Capital invested by funds: $2.01B → $1.72B (-$283M)
24% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$24M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$18.5M |
| 3 |
BlackRock
New York
|
+$16.1M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$15.7M |
| 5 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$7.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$13M |
| 2 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$10.5M |
| 3 |
MIIM
Mesirow Institutional Investment Management
Chicago,
Illinois
|
-$6.27M |
| 4 |
LCG
Lisanti Capital Growth
New York
|
-$5.79M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.85M |
SUPN Hedge Fund Activity: Q2 2023 in Review
249 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2023, worth a combined $1.72B — down 14% from $2.01B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of SUPN and 29 opened new positions — a net loss of 9 holders — while 89 trimmed existing stakes and 91 added.
The largest buyer was Armistice Capital, adding an estimated $24M. The largest seller was Envestnet Asset Management, cutting an estimated $13M.
- 249 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2023, down from 258 in Q1 2023.
- Funds reported $1.72B of Supernus Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
- 29 funds opened new Supernus Pharmaceuticals positions in Q2 2023 and 38 closed out, a net change of -9 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2023 was Armistice Capital, an estimated $24M added.
- The largest Supernus Pharmaceuticals seller in Q2 2023 was Envestnet Asset Management, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2023.